Scientists have appreciated the roles of bacteria in our microbiomes for decades. Now, they’re studying the effects of the trillions of viruses that call the human body home.
Seeking complexity and control, researchers developed a drug consisting of 148 bacterial strains — the largest consortium of its kind to enter clinical trials.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?